Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX4
Background: Over the past decade, survival from advanced colorectal cancer is increasing. Therefore patients have more exposure to chemotherapy and related toxicities. This study determines how hematologic toxicity patterns affect therapy and care. Methods: From April 2010 to March 2013, we enro...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shiraz University of Medical Sciences
2015-07-01
|
| Series: | Middle East Journal of Cancer |
| Subjects: | |
| Online Access: | http://mejc.sums.ac.ir/index.php/mejc/article/view/237/217 |
| Summary: | Background: Over the past decade, survival from advanced colorectal cancer is
increasing. Therefore patients have more exposure to chemotherapy and related
toxicities. This study determines how hematologic toxicity patterns affect therapy
and care.
Methods: From April 2010 to March 2013, we enrolled 127 patients with stages
IIb to IV colorectal cancer. Patients underwent complete blood count monitoring prior
to and during each cycle of FOLFOX4 chemotherapy. Granulocyte colony stimulating
factor was injected if their white blood cells were below 3.5×109/L.
Results: The most common hematologic toxicities were grades 1-2 for hemoglobin
(76.83%) and leukopenia (26.48%). The least common hematologic toxicity was
thrombocytopenia (4.69%) for all grades of platelet toxicity. The median granulocyte
colony stimulating factor injection was 3.33 per 12 cycles.
Conclusion: Anemia and leukopenia are the most common hematologic
abnormalities expected with FOLFOX4 chemotherapy regimens for colorectal cancer.
The most important factor for predicting hematologic toxicities in patients who receive
chemotherapy for colorectal cancer is the number of chemotherapy cycles. |
|---|---|
| ISSN: | 2008-6709 2008-6687 |